The effect of combined modality therapy on local control and survival

V. T. DeVita, Marc E Lippman, S. M. Hubbard, D. C. Ihde, S. A. Rosenberg

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The systemic component of combined modality therapeutic programs has influenced both the selection of the approach to local control and survival in a number of tumor types. The more effective systemic therapy is against metastatic cancer by itself, the greater the impact on local control and survival. This observation is consistent with the invariable inverse relationship between curability and tumor cell number. For some common cancers, local control is good, but survival remains poor because of the inability to deal effectively with micrometastases. Improved systemic treatment is likely to have an impact on survival may shift local control measures, in some cases, to radiation therapy or lesser surgery without radiation therapy. There remains a substantial number of tumor types where both local control and survival is poor. In these tumors, improvement in local control by itself is not likely to improve survival because of the presence of micrometastases, but such improvements must occur before we can have a true evaluation of the systemic treatment of micrometastases in these tumors. The recent understanding that the metastatic process is under genetic control and the cloning of metastases genes offers a substantial opportunity to control this process and influence both local control and survival.

Original languageEnglish
Pages (from-to)487-501
Number of pages15
JournalInternational journal of radiation oncology, biology, physics
Volume12
Issue number4
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Combined Modality Therapy
therapy
Neoplasm Micrometastasis
tumors
Neoplasms
Radiotherapy
radiation therapy
cancer
Therapeutics
metastasis
Organism Cloning
surgery
genes
Cell Count
Neoplasm Metastasis
evaluation
shift
Genes

Keywords

  • Anal cancer
  • Breast cancer
  • Combined modality
  • Lung cancer
  • Lymphoma
  • Sarcomas
  • Wilms' tumor, Systemic therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

The effect of combined modality therapy on local control and survival. / DeVita, V. T.; Lippman, Marc E; Hubbard, S. M.; Ihde, D. C.; Rosenberg, S. A.

In: International journal of radiation oncology, biology, physics, Vol. 12, No. 4, 01.01.1986, p. 487-501.

Research output: Contribution to journalArticle

DeVita, V. T. ; Lippman, Marc E ; Hubbard, S. M. ; Ihde, D. C. ; Rosenberg, S. A. / The effect of combined modality therapy on local control and survival. In: International journal of radiation oncology, biology, physics. 1986 ; Vol. 12, No. 4. pp. 487-501.
@article{217b31f46a4148dbb87ca9f055c55319,
title = "The effect of combined modality therapy on local control and survival",
abstract = "The systemic component of combined modality therapeutic programs has influenced both the selection of the approach to local control and survival in a number of tumor types. The more effective systemic therapy is against metastatic cancer by itself, the greater the impact on local control and survival. This observation is consistent with the invariable inverse relationship between curability and tumor cell number. For some common cancers, local control is good, but survival remains poor because of the inability to deal effectively with micrometastases. Improved systemic treatment is likely to have an impact on survival may shift local control measures, in some cases, to radiation therapy or lesser surgery without radiation therapy. There remains a substantial number of tumor types where both local control and survival is poor. In these tumors, improvement in local control by itself is not likely to improve survival because of the presence of micrometastases, but such improvements must occur before we can have a true evaluation of the systemic treatment of micrometastases in these tumors. The recent understanding that the metastatic process is under genetic control and the cloning of metastases genes offers a substantial opportunity to control this process and influence both local control and survival.",
keywords = "Anal cancer, Breast cancer, Combined modality, Lung cancer, Lymphoma, Sarcomas, Wilms' tumor, Systemic therapy",
author = "DeVita, {V. T.} and Lippman, {Marc E} and Hubbard, {S. M.} and Ihde, {D. C.} and Rosenberg, {S. A.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0360-3016(86)90056-8",
language = "English",
volume = "12",
pages = "487--501",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The effect of combined modality therapy on local control and survival

AU - DeVita, V. T.

AU - Lippman, Marc E

AU - Hubbard, S. M.

AU - Ihde, D. C.

AU - Rosenberg, S. A.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The systemic component of combined modality therapeutic programs has influenced both the selection of the approach to local control and survival in a number of tumor types. The more effective systemic therapy is against metastatic cancer by itself, the greater the impact on local control and survival. This observation is consistent with the invariable inverse relationship between curability and tumor cell number. For some common cancers, local control is good, but survival remains poor because of the inability to deal effectively with micrometastases. Improved systemic treatment is likely to have an impact on survival may shift local control measures, in some cases, to radiation therapy or lesser surgery without radiation therapy. There remains a substantial number of tumor types where both local control and survival is poor. In these tumors, improvement in local control by itself is not likely to improve survival because of the presence of micrometastases, but such improvements must occur before we can have a true evaluation of the systemic treatment of micrometastases in these tumors. The recent understanding that the metastatic process is under genetic control and the cloning of metastases genes offers a substantial opportunity to control this process and influence both local control and survival.

AB - The systemic component of combined modality therapeutic programs has influenced both the selection of the approach to local control and survival in a number of tumor types. The more effective systemic therapy is against metastatic cancer by itself, the greater the impact on local control and survival. This observation is consistent with the invariable inverse relationship between curability and tumor cell number. For some common cancers, local control is good, but survival remains poor because of the inability to deal effectively with micrometastases. Improved systemic treatment is likely to have an impact on survival may shift local control measures, in some cases, to radiation therapy or lesser surgery without radiation therapy. There remains a substantial number of tumor types where both local control and survival is poor. In these tumors, improvement in local control by itself is not likely to improve survival because of the presence of micrometastases, but such improvements must occur before we can have a true evaluation of the systemic treatment of micrometastases in these tumors. The recent understanding that the metastatic process is under genetic control and the cloning of metastases genes offers a substantial opportunity to control this process and influence both local control and survival.

KW - Anal cancer

KW - Breast cancer

KW - Combined modality

KW - Lung cancer

KW - Lymphoma

KW - Sarcomas

KW - Wilms' tumor, Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=0022500819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022500819&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(86)90056-8

DO - 10.1016/0360-3016(86)90056-8

M3 - Article

C2 - 3009367

AN - SCOPUS:0022500819

VL - 12

SP - 487

EP - 501

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -